TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03031483
Drug: clarithromycin and lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Each treatment course will consist of:~Oral Lenalidomide (Revlimid) once daily for 21 days at a dose 20 mg; in case of drug-related adverse events the dose can be reduced to 15 and 10 mg/day; Oral Clarithromycin 500 mg twice daily for 28 days. Courses will be repeated every 28 days. After the first 3 courses patients with stable disease or better response will be given another three courses. Patients with complete remission or disease progression after 6 courses will be taken off study, while patients with partial response or stable disease will receive 3 further courses of treatment. Again, patients with complete response or disease progression will stop therapy, while patients with partial response/stable disease will receive 3 further courses up to a maximum of 12 courses in total.
Study: NCT00353496
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution 0.9% administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.
Study: NCT03997123
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: Oral tablets. 400 mg of Placebo (2 tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 2 to 5 of Weeks 1, 2, and 3 followed by 1 week offtreatment within each 28-day treatment cycle
Study: NCT03127514
Drug: AMX0035
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMX0035
Study: NCT04105010
Drug: AZD4205
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4205 will be administered orally as capsules. AZD4205 treatment will be continued until disease progression or intolerant adverse reactions
Study: NCT02738138
Drug: ABT-493 coformulated with ABT-530
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT01638910
Drug: EV/DNG (Qlaira, BAY86-5027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol valerate and dienogest (2 days 3.0 mg estradiol valerate (EV), 5 days 2.0 mg EV + 2.0 mg dienogest (DNG), 17 days 2.0 mg EV + 3.0 mg DNG, 2 days 1.0 mg EV, 2 days placebo), one table oral daily for 13 treatment cycles (1 cycle = 28days)
Study: NCT04335045
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1\~8 Placebo capsule(s) corresponding to each PH100 dose
Study: NCT04335045
Drug: PH100 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 100 mg PH100 oral capsule
Study: NCT04335045
Drug: PH100 200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 200 mg PH100 oral capsule
Study: NCT04335045
Drug: PH100 400mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 200 mg PH100 oral capsules
Study: NCT04335045
Drug: PH100 800mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 x 200 mg PH100 oral capsules
Study: NCT04335045
Drug: PH100 1200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 x 200 mg PH100 oral capsules
Study: NCT04335045
Drug: PH100 1600mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 x 200 mg PH100 oral capsules
Study: NCT03522142
Drug: INCB081776
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB081776 administered once or twice daily orally with water after a fast of at least 2 hours before and at least 1 hour after the dose.
Study: NCT03522142
Drug: INCMGA00012
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCMGA0012 administered intravenously according to the label as 500 mg every 4 weeks
Study: NCT06798051
Drug: Roxithromycin tablets 150mg
Normalized name: roxithromycin
DrugBank: Roxithromycin (DB00778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral roxithromycin tablets，150mg Once every seven days，One cycle T drug, two cycles R drug
Study: NCT03907826
Drug: GP
Normalized name: GPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1.0g/m2, D1 and D8; Cisplatin 80mg/m2, D1, every 3 weeks per cycle, total three cycles
Study: NCT02890355
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02890355
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV bolus
Study: NCT02890355
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03524092
Drug: Placebo SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04224246
Drug: Gamma Hydroxybutyrate
Normalized name: Gamma hydroxybutyrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma-OH® will be administered intravenously at a dose of 20 mg/kg/h for 6 hours
Study: NCT04299191
Drug: LAM561
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a patient is allocated a dose of LAM561, they will receive the same dose on a daily basis in treatment cycles of 21 days (3 weeks), which may be repeated without therapy interruption until a criterion for discontinuation (clinical or radiological progression of disease, clinically unacceptable toxicity, or another general criterion) is met.~The starting dose will be 2.8 g/m2 twice daily. If tolerated, doses will be escalated to 3.5 g/m2 twice daily and then to a third dose level of 4.2 g/m2 twice daily. These dose levels correspond to 80%, 100%, and 120% of the maximum tolerated dose of LAM561 in adult patients when adjusted for body surface area. A total of 3 dose cohorts are anticipated for the dose escalation phase of the study, with up to 6 patients enrolled at each dose level according to a standard 3+3 design. During each dose cohort, at least 1 week must elapse between the first and subsequent patients receiving treatment with LAM561.
Study: NCT03971669
Drug: Vivotif Typhoid Oral Vaccine
Normalized name: Vivotif Typhoid Oral Vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).
Study: NCT00001452
Drug: oCRH
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02533973
Drug: Xamiol® gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02533973
Drug: Daivonex® scalp solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02415127
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The volume of placebo is planned to correspond with volume of study drug that would be given to the participant if the participant was randomized to the study drug arm.
Study: NCT06745986
Drug: Spinal Anesthesia (bupivacaine)
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: spinal anesthesia by 2.5 ml bupivacaine 0.5%
Study: NCT03133195
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo subcutaneous once daily for 12 weeks. (Patient self administration at home by pen injector)
Study: NCT01855750
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 matched capsules administered by mouth once daily (21-day cycles)
Study: NCT01855750
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
Study: NCT01855750
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
Study: NCT02905942
Drug: PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-rhG-CSF was given day +1 after autologous stem cell transplantation with a dose of 100μg/kg(bw).For patients more than 45kg, 6mg was suggested.
Study: NCT04303117
Drug: M7824
Normalized name: M7824
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg administered IV every two weeks while on NHS-IL12.
Study: NCT00650078
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1x daily
Study: NCT03703271
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: single-agent 5-day methotrexate, two weeks a cycle
Study: NCT04043494
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part of standard chemotherapy and included in the experimental treatment phase protocol Ib\* (Randomization 2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
Study: NCT04043494
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part of standard chemotherapy
Study: NCT04043494
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib\* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2)
Study: NCT04043494
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No involvement of CNS: Part of standard chemotherapy. Involvement of CNS: Part of standard chemotherapy and included in the experimental treatment phase Protocol Ia-Dexamethasone (Randomization R1), in the experimental treatment phase Protocol Ib\* (Randomization R2) and in the experimental treatment phase Intensified Protocol M (Randomization R2
Study: NCT02513394
Drug: Standard Adjuvant Endocrine Therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02017613
Drug: RP6530
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses starting at 25 mg BID
Study: NCT00344955
Drug: HMG-CoA reductase inhibition (atorvastatin)
Normalized name: HMG CoA reductase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00448760
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenuosly, 500mg/m2, continuous infusion over 24 hours, 2 cycles
Study: NCT03274297
Drug: EVRA patch (NGMN+EE) (Treatment A) (Reference)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single transdermal contraceptive patch of EVRA (NGMN + EE) containing 6 milligram (mg) of the progestin NGMN and 600 microgram (mcg) of the EE will be applied to the buttock (right or left) of participants on Day 1 of each treatment period and is removed 7 days after patch application, ie, on Day 8.
Study: NCT03274297
Drug: HMW PIB patch (NGMN+EE) (Treatment B) (Test)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single transdermal contraceptive HMW PIB (NGMN + EE) patch containing 6 mg of the progestin NGMN and 600 mcg of the EE will be applied to the buttock (right or left) of participants on Day 1 of each treatment period and is removed 7 days after patch application, ie, on Day 8.
Study: NCT03632213
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group: 15 patients, both sexes, will receive oral placebo for 12 months.
Study: NCT01699815
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02521415
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal (IN) fentanyl (1.5 micrograms/kg)
Study: NCT02521415
Drug: ibuprofen or acetaminophen
Normalized name: acetaminophen / ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg of ibuprofen or 15 mg/kg of acetaminophen will be given to participants prior to the randomized intervention
Study: NCT01867892
Drug: ICT of oxapliplatin, irinotecan, leucovorin, and fluorouracil and CCRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxapliplatin ,irinotecan ,5FU +leucovorin ,RT 5,040cGy in 28 fractions/5.5 wks and 5FU 450mg/m2 iv 30min weekly
Study: NCT03962894
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During a sequenced rollout protocol change for several EMS agencies, those agencies will adopt protocol change to administer prednisolone to children with asthma attacks in the prehospital environment prior to ED arrival.
Study: NCT03973229
Drug: Estradiol patch
Normalized name: Estradiol Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol (E2) patches at a dose of 100ug will be applied 24-48 hours before the MRI scan is performed.
Study: NCT04168892
Drug: 225 IU of HMG in patients with age > 35 years
Approvals — FDA: no, EMA: no, PMDA: no
Description: The use of a different starting dose, based on the female age, derives from the necessity to control the effect of a variable starting dose on the primary outcome.
Study: NCT04205565
Drug: Placebo group: Placebo Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection of l-oxiracetam, 4 vials, once a day, IV. Placebo injection of oxiracetam, 6 vials, once a day, IV.
Study: NCT03556592
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1x 100 mg tablet
Study: NCT02281422
Drug: BIA 2-093
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02905591
Drug: Radiation Therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conformal radiation administered daily, Monday through Friday Total dose is 60 Gray (Gy) and is delivered in 2 Gy fractions. One fraction is delivered daily for a total of 30 fractions in 30 days
Study: NCT02905591
Drug: Ascorbic Acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously~* 75 grams per infusion; each infusion is about 2 hours~* 3 infusion per calendar week~* The infusion is actively running for at least 20 minutes when radiation begins~* May be given while chemotherapy is delayed due to low counts~* Dose reductions are not used~* Given for 6 to 7 weeks, depending on when radiation starts
Study: NCT03514108
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets x 3 daily
Study: NCT03514108
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily)
Study: NCT03761173
Drug: Anticoagulation Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation medication
Study: NCT03713879
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rectally administered indomethacin before or after ERCP
Study: NCT02864550
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: doxycycline 100mg orally daily
Study: NCT04454866
Drug: Single injection of penehyclidine
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dose of penehyclidine hydrochloride (0.5 mg/5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
Study: NCT04454866
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dose of placebo (normal saline 5 ml) is injected intravenously before anesthesia induction. A patient-controlled intravenous analgesia pump is provided after surgery, which is established with a mixture of placebo (normal saline 5 ml), sufentanil (1.25-1.5 ug/kg) and tropisetron (10 mg), diluted with normal saline to 100 ml, and programmed to administer a continuous infusion at a rate of 2 ml/h for 48 hours.
Study: NCT01483924
Drug: Apo805K1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential parallel dose escalation.
Study: NCT02017340
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8mg Placebo tablet taken once a day at lunch time for 78 weeks
Study: NCT02014714
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug: Fentanyl 40mcg Depending on the randomization schedule, 40μg of fentanyl will be added to the intrathecal mixture.
Study: NCT02325492
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04148495
Drug: placebo of acetaminophen IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mophine IV: Initial loading dose of 0.1 mg/kg (ensuring that the maximum dose of 10 mg is not exceeded) followed by bolus of 0.05 mg/kg every 10 minutes (taking care not to exceed the maximum dose of 5 mg) as reported by the recommandation of experts of the french society of urgency care.~Placebo of acetaminophen IV: Sodium chloride 0.9%
Study: NCT04148495
Drug: acetaminophen IV
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mophine IV: Initial loading dose of 0.1 mg/kg (ensuring that the maximum dose of 10 mg is not exceeded) followed by bolus of 0.05 mg/kg every 10 minutes ((taking care not to exceed the maximum dose of 5 mg) as reported by the recommandation of experts of the french society of urgency care.~Acetaminophen IV: 1 g
Study: NCT02154763
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02045238
Drug: Hypertonic Saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Chloride 3% solution, previously prepared in 5 mL syringes.
Study: NCT01311960
Drug: normal saline 0.9%
Normalized name: BD Posiflush Normal Saline 0.9% Prefilled Syringe Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline eye drop 0.9% will apply 4 times a day for 3 months.
Study: NCT00739349
Drug: vehicle/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: vehicle/placebo
Study: NCT00965432
Drug: STX107
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of an oral suspension
Study: NCT00737126
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of a daily tablet containing 5 mg of folic acid for 4 months.
Study: NCT00737126
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of an oral placebo pill
Study: NCT01986465
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02615574
Drug: CKM
Normalized name: BUCKMINSTERFULLERENE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive one cycle of CKM alone followed by three cycles of vaccine + CKM.
Study: NCT04435665
Drug: NFX-179 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: gel for topical administration
Study: NCT04435665
Drug: Vehicle Gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: vehicle gel for topical administration
Study: NCT04351867
Drug: docetaxel plus oxaliplatin and capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: docetaxel 50mg/㎡ ivgtt. d1+oxaliplatin 100mg/㎡ ivgtt. d1+capecitabine 1000mg/㎡ bid p.o. d1-d14 q21d
Study: NCT04351867
Drug: oxaliplatin plus capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oxaliplatin 130mg/㎡ ivgtt. d1+capecitabine 1000mg/㎡ bid p.o. d1-d14 q21d
Study: NCT03505905
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In a sequential parallel comparison design, in a double blind placebo controlled study, the efficacy of pregnenlone treatment relative to placebo in improving depression and anxiety symptoms, cognition, sleep, quality of life and vasomotor symptoms in preimenopausal and menopausal women with MDD.
Study: NCT03221426
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT03221426
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral tablets
Study: NCT03221426
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion
Study: NCT00419263
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (2 injections of placebo).
Study: NCT01511848
Drug: DFP, DFO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Deferoxamine It will be administered subcutaneously over 8 hours for 5 days at a dose of 40 mg/kg.~Other Name: Desferal, DFO Drug: DFP DFP: will be orally administered at a dose of 75mg/kg orally in 3 divided doses for 7 days
Study: NCT01383733
Drug: RO5458640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple ascending doses intravenously, weekly or every 2 weeks or every 3 weeks
Study: NCT01163097
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin continuous IV infusion
Study: NCT03260166
Drug: nicotinamide
Normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: nicotinamide; Pharmaceutical form: tablet; Route of administration: oral
Study: NCT01027000
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01027000
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04092270
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT04092270
Drug: Peposertib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01297166
Drug: LEO 27989 ointment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: once daily application, 3weeks
Study: NCT04477629
Drug: Corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-experimental: CS is part of standard of care after heart transplant and will follow dosing recommendations as per standard clinical practice at a dose no less than 5mg/d.
Study: NCT02609048
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Capsule